Description:
01.Sommarlutide is a long-acting formulation based on the basic
structure of Liraglutide, which is more effective in the treatment of
type 2 diabetes..
02.Semeglutide is a GLP-1(7-37) chain with 8-position Aib replacing
Ala, 34-position Arg replacing Lys, and 26-position Lys attached to the
stearic acid fatty chain.
03.Compared with Liraglutide, Semeglutide's fat Chemicalbook chain
is longer and its hydrophobicity is increased, but Semeglutide is
modified with short chain PEG and its hydrophilicity is greatly
enhanced.
04.After PEG modification, it can not only bind to albumin closely,
cover the hydrolysis site of DPP-4 enzyme, but also reduce renal
excretion, prolong biological half-life, and achieve a long cycle
effect.
USD:
Se maglutide (Rybelsus, O zempic, NN9535, OG217SC, NNC 0113-0217) is
a long-acting glucagon-like peptide 1 (GLP-1) analogue and agonist of
the GLP-1 receptor. It has potential therapeutic efficacy for type 2
diabetes mellitus (T2DM).